Phase II study of erlotinib and modified FOLFOX-6 (5-fluorouracil, leucovorin [folinic acid] and oxaliplatin) in previously untreated patients with unresectable or metastatic adenocarcinoma of the esophagus and gastric cardia
Phase of Trial: Phase II
Latest Information Update: 05 Nov 2015
At a glance
- Drugs Erlotinib; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Gastric cancer; Gastrointestinal cancer; Oesophageal cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 02 Nov 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 26 Jul 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.